Natural history of COVID-19 and therapeutic options

P Gautret, M Million, PA Jarrot… - Expert review of …, 2020 - Taylor & Francis
Introduction: COVID-19 presents benign forms in young patients who frequently present with
anosmia. Infants are rarely infected, while severe forms occur in patients over 65 years of …

[HTML][HTML] Hajj: infectious disease surveillance and control

…, KD Al Harby, M Alyemni, K Dhafar, P Gautret… - The Lancet, 2014 - thelancet.com
Religious festivals attract a large number of pilgrims from worldwide and are a potential risk
for the transmission of infectious diseases between pilgrims, and to the indigenous …

[HTML][HTML] Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review

TL Dao, VT Hoang, P Gautret - European Journal of Clinical Microbiology …, 2021 - Springer
… be older (median age = 64 versus 57 years, p = 0.093) and had a significantly longer nucleic
acid conversion time (36 versus 21 days; p < 0.001). Most of these 15 patients experienced …

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

P Gautret, JC Lagier, P Parola, L Meddeb… - International journal of …, 2020 - Elsevier
… only, and 12.5% in the control group (p<0.001). These results are summarized in Fig. 1, Fig.
… of URTI and LRTI, as compared to asymptomatic patients with p<0.05 (data not shown). …

[HTML][HTML] Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

…, VT Hoang, C Grimaldier, P Colson, P Gautret… - European Journal of …, 2020 - Springer
In a preliminary clinical study, we observed that the combination of hydroxychloroquine and
azithromycin was effective against SARS-CoV-2 by shortening the duration of viral load in …

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France

M Million, JC Lagier, P Gautret, P Colson… - Travel medicine and …, 2020 - Elsevier
… Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher
viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were …

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot …

P Gautret, JC Lagier, P Parola, L Meddeb… - Travel medicine and …, 2020 - Elsevier
Background We need an effective treatment to cure COVID-19 patients and to decrease
virus carriage duration. Methods We conducted an uncontrolled, non-comparative, …

[HTML][HTML] Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis

JC Lagier, M Million, P Gautret, P Colson… - Travel medicine and …, 2020 - Elsevier
Background In our institute in Marseille, France, we initiated early and massive screening
for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with …

Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel …

…, L Weld, A Goorhuis, P Gautret… - The Lancet Infectious …, 2015 - thelancet.com
Background Travel is important in the acquisition and dissemination of infection. We aimed
to assess European surveillance data for travel-related illness to profile imported infections, …

Global perspectives for prevention of infectious diseases associated with mass gatherings

I Abubakar, P Gautret, GW Brunette… - The Lancet infectious …, 2012 - thelancet.com
We assess risks of communicable diseases that are associated with mass gatherings (MGs),
outline approaches to risk assessment and mitigation, and draw attention to some key …